No Benefit Adding Cetuximab to Chemo for Stage III Colon Cancer

Adding Erbitux® (cetuximab) to standard chemotherapy for stage III colon cancer didn’t improve patient outcomes and added more side effects. All of the patients in the NO147 trial had cancer that had spread to their lymph nodes and had surgery…  Read More

No Difference in Chemotherapy Benefits for Young Patients with Stage II and III Colon Cancer Compared to Those Fifty and Older

Young patients with stage II or III colon cancer get equal benefit from chemotherapy as older patients, and they have similar side effects. Five years after treatment, 67 percent of patients under the age of fifty hadn’t had their cancer…  Read More

ASCO Research Highlights: Molecular Markers in Stage II and III Colon Cancer

Several studies presented at ASCO looked a biomarkers that might predict cancer recurrence or patient survival in stage II and III colon cancer and whether patients could be chosen to receive chemotherapy based on those markers.  Of special interest was…  Read More

Adding Irinotecan to Infusional 5-FU Does Not Add Benefit for Stage III Colon Cancer

Five years after surgery, there was no improvement in either disease-free survival or overall survival when irinotecan was added to standard 5-FU treatments delivered via continous infusion for patients with stage III colon cancer.  Adding irinotecan increased the rate of…  Read More